Trial Profile
Randomized, double-blind, placebo-controlled, multi-center, sequential cohort study to evaluate the effect of SLV320 in addition to chronic furosemide treatment on renal function in subjects with congestive heart failure and impaired renal function.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs SLV 320 (Primary)
- Indications Heart failure
- Focus Biomarker; Therapeutic Use
- Sponsors Abbott Healthcare Products
- 25 Mar 2008 Status changed from suspended to discontinued.
- 15 Feb 2008 Status changed from recruiting to suspended, as reported in ClinicalTrials.gov.
- 20 Dec 2007 New trial record.